The effect of the interferon‐γ‐inducible processing machinery on the generation of a naturally tumor‐associated human cytotoxic T lymphocyte epitope within a wild‐type and mutant p53 sequence context

The human wild‐type (wt) p53.264–272 peptide is a universal tumor antigen and recognized by HLA‐A*0201 (A2.1)‐restricted CTL. Generation of this epitope by constitutive 20S proteasomes is prevented by a p53 R to H hotspot mutation at the C‐terminal flanking residue 273. We report on the impact of the interferon‐γ (IFN‐γ)‐inducible proteasomal activator PA28 (11S regulator) and the immunoproteasome on the in vitro and cellular processing of wt and mutant (mut) p53 substrates. We found that production of the antigenic 264–272 peptide from wt p53 by constitutive as well as immunoproteasomes is accelerated and amplified by the PA28 activator. PA28 and (immuno)proteasomes were not capable to reconvert the resistance of epitope release from mut p53. Maximum and accelerated antigen production in vitro and on the cellular level required the IFN‐γ‐inducible interaction of immunoproteasomes and PA28. We conclude that efficient processing of p53.264272 from wt p53 is governed by the proteasome/PA28 complex. These studies have important implications for p53‐specific cancer immunotherapy and demonstrate that the effects of the immunoproteasome and PA28 are influenced by the individual epitope and its flanking sequence context.

[1]  C. Slaughter,et al.  Primary structures of two homologous subunits of PA28, a γ‐interferon‐inducible protein activator of the 20S proteasome , 1995, FEBS letters.

[2]  P. Kloetzel,et al.  Molecular cloning of the mouse proteasome subunits MC14 and MECL‐1: reciprocally regulated tissue expression of interferon‐γ‐modulated proteasome subunits , 1997, European journal of immunology.

[3]  Hans-Georg Rammensee,et al.  Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands , 1996, Cell.

[4]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[5]  Y. Murakami,et al.  Hybrid Proteasomes , 2000, The Journal of Biological Chemistry.

[6]  P. Kloetzel,et al.  Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes , 2000, The Journal of experimental medicine.

[7]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[8]  Marcus Groettrup,et al.  Incorporation of major histocompatibility complex – encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon‐γ , 1995, European journal of immunology.

[9]  Keiji Tanaka,et al.  Double‐cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region , 1997, Genes to cells : devoted to molecular & cellular mechanisms.

[10]  H. Rammensee,et al.  Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products , 2001, The Journal of experimental medicine.

[11]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[12]  M. Bevan,et al.  In thymic selection, peptide diversity gives and takes away. , 1997, Immunity.

[13]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[14]  A. Goldberg,et al.  Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Dahlmann,et al.  Reconstitution of proteasome activator PA28 from isolated subunits: optimal activity is associated with an α,β‐heteromultimer , 1996 .

[16]  A. Levine,et al.  Targeting p53 as a general tumor antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Neefjes,et al.  The proteasome‐specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells , 1997, European journal of immunology.

[18]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[19]  Peter M. Kloetzel,et al.  MHC Class I Antigen Processing of an Adenovirus CTL Epitope Is Linked to the Levels of Immunoproteasomes in Infected Cells1 , 2000, The Journal of Immunology.

[20]  C. Huber,et al.  Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. , 1999, Cancer research.

[21]  A. Goldberg,et al.  Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.

[22]  Hans-Georg Rammensee,et al.  A role for the proteasome regulator PA28α in antigen presentation , 1996, Nature.

[23]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[24]  P M Kloetzel,et al.  Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes , 1994, The Journal of experimental medicine.